Historically, patients diagnosed with castration-resistant prostate cancer (CRPC) have had poor survival rates. In recent years there have been significant advances in the treatment of CRPC. In ...
Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial responses, almost all patients progress to castration-resistant prostate cancer (CRPC). The understanding of ...
In a recent MedPage Today video, Neeraj Agarwal, MD, of the Huntsman Cancer Institute at the University of Utah in Salt Lake City, reviewed the TALAPRO-2 trial's implications for frontline treatment ...
obese man, overweight, obesity, AUA 2017, urology, nephrology Obese men with non-metastatic castration-resistant prostate cancer have a 21% decreased risk of death compared with normal weight men, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback